Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses

Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged < 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gridelli, C, Frontini, L, Perrone, F, Gallo, C, Gulisano, M, Cigolari, S, Castiglione, F, Robbiati, S F, Gasparini, G, Ianniello, G P, Farris, A, Locatelli, M C, Felletti, R, Piazza, E
Formato: Artigo
Idioma:English
Publicado: Nature Publishing Group 2000
Assuntos:
Regular Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363528/
https://ncbi.nlm.nih.gov/pubmed/10952772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2000.1341
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC2363528/
https://ncbi.nlm.nih.gov/pubmed/10952772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2000.1341

Títulos similares